Insider Selling: Amgen (NASDAQ:AMGN) SVP Sells 1,252 Shares

Amgen Inc. (NASDAQ:AMGN) SVP Rachna Khosla sold 1,252 shares of the stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $416.43, for a total value of $521,370.36. Following the sale, the senior vice president owned 6,404 shares in the company, valued at approximately $2,666,817.72. This trade represents a 16.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Rachna Khosla also recently made the following trade(s):

• On Tuesday, August 11th, Rachna Khosla sold 2,000 shares of Amgen stock. The stock was sold at an average price of $412.57, for a total transaction of $825,140.00.

Amgen Trading Up 0.4%

AMGN stock traded up $1.66 during trading on Thursday, hitting $417.84. The company had a trading volume of 2,777,498 shares, compared to its average volume of 2,729,039. The firm has a 50-day moving average price of $369.26 and a 200-day moving average price of $358.53. Amgen Inc. has a 12 month low of $269.77 and a 12 month high of $421.79. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. The stock has a market cap of $225.90 billion, a price-to-earnings ratio of 25.97, a PEG ratio of 3.87 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, topping the consensus estimate of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The company had revenue of $10.05 billion during the quarter, compared to analysts’ expectations of $9.43 billion. During the same quarter in the previous year, the company earned $6.02 EPS. Amgen’s revenue was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, analysts predict that Amgen Inc. will post 22.78 earnings per share for the current year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 21st will be issued a $2.52 dividend. The ex-dividend date of this dividend is Friday, August 21st. This represents a $10.08 annualized dividend and a dividend yield of 2.4%. Amgen’s payout ratio is 62.65%.

Wall Street Analysts Forecast Growth

AMGN has been the subject of several research analyst reports. Truist Financial upped their price target on shares of Amgen from $340.00 to $362.00 and gave the company a “hold” rating in a report on Wednesday, August 5th. The Goldman Sachs Group set a $389.00 target price on shares of Amgen in a research note on Friday, June 5th. UBS Group increased their target price on Amgen from $420.00 to $440.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Cantor Fitzgerald reissued a “neutral” rating and issued a $350.00 price target on shares of Amgen in a research note on Monday, July 6th. Finally, Bank of America boosted their price target on shares of Amgen from $312.00 to $317.00 and gave the stock an “underperform” rating in a research report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, fifteen have given a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $371.68.

Institutional Investors Weigh In On Amgen

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Norges Bank acquired a new stake in shares of Amgen during the 4th quarter worth about $2,164,162,000. Capital World Investors boosted its holdings in shares of Amgen by 22.9% during the 4th quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock worth $7,560,249,000 after buying an additional 4,302,237 shares during the period. BlackRock Inc. grew its stake in Amgen by 4.8% in the 2nd quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company’s stock valued at $17,874,974,000 after buying an additional 2,261,544 shares during the last quarter. State Street Corp raised its holdings in Amgen by 4.4% in the 4th quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock valued at $10,012,872,000 after acquiring an additional 1,287,310 shares during the period. Finally, Geode Capital Management LLC lifted its position in Amgen by 7.8% during the fourth quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock worth $4,665,822,000 after acquiring an additional 1,035,779 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.